



**JENNER
VACCINE TRIALS**
NUFFIELD DEPARTMENT OF MEDICINE



ChAdOx1 nCoV-19 WHO

08/02/21

data cut 7th December

NIHR | National Institute
for Health Research



UK Research
and Innovation

CEPI

AstraZeneca 



New variants

- UK – B.1.1.7
- South Africa – B.1.351
- Brazil – P.1






Hospitalisation




	N cases	ChAdOx1 nCoV-19 N=12408	Control N=12104
< 22 days after a single dose	9	2	7
>= 22 days after the first dose and < 15 days post booster dose	6	0	6
>= 15 days post booster dose	9	0	9
Total	24	2	22



B.1.1.7




Non-B.1.1.7





Kent Variant

Figure 6. Live virus microneutralisation antibody titres of sera against B.1.1.7 and a canonical non-B.1.1.7 (Victoria) strain





	Variant	N (%)	ChAdOx1 nCoV-19	Control	VE 95%CI	
Primary Symptomatic COVID-19						
	B.1.1.7	34 (14%)	7/4236	27/4270	74.6% (41.6%, 88.9%)	
	Other variants	86 (34%)	12/4236	74/4270	84.1% (70.7%, 91.4%)	

